Table 5 Differences between high-risk and low-risk patients’ preferences for osteoporosis drug treatment
From: Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment
Attributes and levels | High risk patients | Low-risk patients | P valuea |
|---|---|---|---|
(FRAX major >10%) | (FRAX major ≤10%) | ||
Number of patients | 139 | 114 | |
Pseudo-R2 | 0.39 | 0.42 | |
Log-likelihood | -1,378.35 | -1,085.55 | |
Constant | 1.50*** (1.17 to 1.83) | -0.05 (–0.52 to 0.43) | 0.01 |
Efficacy (1% risk reduction) | 0.04*** (0.03 to 0.04) | 0.14*** (0.11 to 0.17) | 0.00 |
SD: 1.65*** | SD: 1.01*** | ||
Cost per month (€1) | -0.02*** (–0.02 to –0.03) | -0.08*** (–0.06 to –0.09) | 0.00 |
SD: 1.45*** | SD: 0.67*** | ||
Drug administration (reference level: weekly oral tablet) | |||
Monthly oral tablet | 0.57** (0.08 to 1.06) | 1.14*** (0.47 to 1.82) | 0.14 |
SD: 0.94*** | SD: 1.87*** | ||
Subcutaneous injection 3-monthly | 0.14 (–0.19 to 0.47) | 0.28 (–0.17 to 0.74) | 0.14 |
SD: NS | SD: NS | ||
Subcutaneous injection 6-monthly | 0.57*** (0.17 to 0.96) | 1.55*** (0.97 to 2.14) | 0.06 |
SD: NS | SD: NS | ||
Intravenous injection 3-monthly | -0.28 (–0.88 to 0.31) | -0.24 (–1.39 to 0.91) | 0.25 |
SD: 1.82*** | SD: 4.84*** | ||
Intravenous injection yearly | 0.28 (–0.13 to 0.69) | 0.75** (0.05 to 1.45) | 0.33 |
SD: 0.81*** | SD: 2.15*** | ||
Side effects (reference level: gastrointestinal disorders) | |||
Flu-like symptoms | 0.66*** (0.36 to 0.95) | 1.51*** (1.07 to 1.95) | 0.57 |
SD: 0.91*** | SD: 1.18*** | ||
Skin reactions | 0.45** (0.05 to 0.85) | 0.49** (0.10 to 0.87) | 0.05 |
SD: 1.31*** | SD: 1.04*** | ||